Top

Published in:

Open Access 01-09-2020 | Chloroquin | Review

The Pharmacokinetic and Pharmacodynamic Properties of Hydroxychloroquine and Dose Selection for COVID-19: Putting the Cart Before the Horse

Authors: Taylor Morrisette, Thomas P. Lodise, Marc H. Scheetz, Srijib Goswami, Jason M. Pogue, Michael J. Rybak

Published in: Infectious Diseases and Therapy | Issue 3/2020

Abstract

Coronavirus disease 2019 (COVID-19), caused by the 2019 novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is currently responsible for a global pandemic. To date, only remdesivir and dexamethasone have demonstrated a positive response in a prospective, randomized trial for the treatment of patients with COVID-19. Hydroxychloroquine (HCQ) is an agent available in an oral formulation with in vitro activity against SARS-CoV-2 that has been suggested as a potential agent. Unfortunately, results of randomized trials evaluating HCQ as treatment against a control group are lacking, and little is known about its pharmacokinetic/pharmacodynamic (PK/PD) profile against SARS-CoV-2. The objective of this review was to describe the current understanding of the PK/PD and dose selection of HCQ against SARS-CoV-2, discuss knowledge gaps, and identify future studies that are needed to optimize the efficacy and safety of treatments against COVID-19.

World Health Organization (2020) WHO Timeline—COVID-19 [Internet]. https://www.who.int/news-room/detail/27-04-2020-who-timeline---covid-19

Guan WJ, Ni ZY, Liang WH, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020. https://doi.org/10.1056/NEJMoa2002032.CrossRefPubMedPubMedCentral

Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JM. Pharmacologic treatments for coronavirus disease 2019 (COVID-19). JAMA. 2020. https://doi.org/10.1001/jama.2020.6019.CrossRef

Beigel JH, Tomashek KM, Dodd LE, et al. (2020) Remdesivir for the treatment of COVID-19—preliminary report. N Engl J Med NEJMoa2007764

Zhang C, Wu Z, Li JW, Zhao H, Wang CG. The cytokine release syndrome (CRS) of severe COVID-19 and interleukin-6 receptor (IL-6R) antagonist tocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents. 2020. https://doi.org/10.1016/j.ijantimicag.2020.105954.CrossRefPubMedPubMedCentral

Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Viro J. 2005;2:69.CrossRef

Fantini J, Scala CD, Chahinian H, Yahu N. Structural and molecular modeling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection. Int J Antimicrob Agents. 2020;55:105960.CrossRef

Al-Bari MA. Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions, and toxic manifestations from malaria to multifarious diseases. J Antimicrob Chemother. 2015;70:1608–21.CrossRef

Tett SE, Day RO, Cutler DJ. Concentration-effect relationship of hydroxychloroquine in rheumatoid arthritis-a cross sectional study. J Rheumatol. 1993;20:1874–9.PubMed

10.

Carmichael SJ, Charles B, Tett SE. Population pharmacokinetics of hydroxychloroquine in patients with rheumatoid arthritis. Ther Drug Monit. 2003;25:671–81.CrossRef

11.

Tett SE, Cutler DJ, Day RO, Brown KF. Bioavailability of hydroxychloroquine tablets in healthy volunteers. Br J Clin Pharmacol. 1989;27:771–9.CrossRef

12.

Fan HW, Ma ZX, Chen J, Yang XY, Cheng JL, Li YB. Pharmacokinetics and bioequivalence study of hydroxychloroquine sulfate tablets in Chinese healthy volunteers by LC-MS/MS. Rheumatol Ther. 2015;2:183–95.CrossRef

13.

Lim HS, Im JS, Cho JY, et al. Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax. Antimicrob Agents Chemother. 2009;53:1468–75.CrossRef

14.

Arshad S, Kilgore P, Chaudhry ZS, et al. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. Int J Infect Dis. 2020;S1201–9712(20):30534–8. https://doi.org/10.1016/j.ijid.2020.06.099.CrossRef

15.

Geleris J, Sun Y, Platt J, et al. Observational study of hydroxychloroquine in hospitalized patients with COVID-19. N Engl J Med. 2020;382:2411–8.CrossRef

16.

World Health Organization (2020) “Solidarity” clinical trial for COVID-19 treatments [Internet]. World Health Organization. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments

17.

Center for Drug Evaluation and Research (2020) FDA cautions use of hydroxychloroquine/chloroquine for COVID-19 [Internet]. U.S. Food and Drug Administration. FDA. https://www.fda.gov/drugs/drug-safety-and-availability/fda-cautions-against-use-hydroxychloroquine-or-chloroquine-covid-19-outside-hospital-setting-or

18.

ClinicalTrials.gov [Internet] (2020) Bethesda (MD): National Library of Medicine (US). 2000 Feb 29- . Identifier NCT04321616, The efficacy of different anti-viral drugs in COVID-19 infected patients; [about 6 screens]. https://clinicaltrials.gov/ct2/show/NCT04321616.

19.

Plaquenil [package insert] (2017) Concordia Pharmaceuticals Inc., St. Michael, Barbados

20.

Tett SE, Cutler DJ, Day RO. Bioavailability of hydroxychloroquine tablets assessed with deconvolution techniques. Pharm Sci. 1992;81:155–9.CrossRef

21.

Institute for Safe Medication Practices (ISMP) (2020) Oral dosage forms that should not be crushed. https://www.ismp.org/recommendations/do-not-crush. Accessed 20 Apr 2020

22.

McLachlan AJ, Cutler DJ, Tett SE. Plasma protein binding of the enantiomers of hydroxychloroquine and metabolites. Eur J Clin Pharmacol. 1993;44:481–4.CrossRef

23.

Tett SE, Cutler DJ, Day RO, Brown KF. A dose-ranging study of the pharmacokinetics of hydroxy-chloroquine following intravenous administration to healthy volunteers. Br J Clin Pharmacol. 1988;26:303–13.CrossRef

24.

Popert AJ. Chorloquine: a review. Rheumatology. 1976;15:235–8.CrossRef

25.

Maisonnasse P, Guedj J, Contreras V, et al. Hydroxychloroquine in the treatment and prophylaxis of SARS-CoV-2 infection in non-human primates. 2020. https://doi.org/10.21203/rs.3.rs-27223/v1 (Pre-print).

26.

Projean D, Baune B, Farinotti R, et al. In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation. Drug Metab Dispos. 2003;31:748–54.CrossRef

27.

Bauman JL, Tisdale JE. Chloroquine and hydroxychloroquine in the era of SARS-CoV2: caution on their cardiac toxicity. Pharmacother. 2020;40(5):387–8. https://doi.org/10.1002/phar.2387.CrossRef

28.

Kalia S, Dutz JP. New concepts in antimalarial use and mode of action in dermatology. Dermatol Ther. 2007;20:160–74.CrossRef

29.

McChesney EW, Conway WD, Banks WF, et al. Studies of the metabolism of some compounds of the 4-amino-7-chloroquinoline series. J Pharmacol Exp Ther. 1966;151:482–93.PubMed

30.

Lee JY, Vinayagamoorthy N, Han K, et al. Association of polymorphisms of cytochrome P450 2D6 with blood hydroxychloroquine levels in patients with systemic lupus erythematosus. Arthritis Rheumatol. 2016;68:184–90.CrossRef

31.

Xu C, Zhu L, Chan T, et al. Chloroquine and hydroxychloroquine are novel inhibitors of human organic anion transporting polypeptide 1A2. J Pharm Sci. 2016;105:884–90.CrossRef

32.

Tiberghien F, Loor F. Ranking of p-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay. Anticancer Drugs. 1996;7:568–78.CrossRef

33.

Cutler DJ, MacIntyre AC, Tett SE. Pharmacokinetics and cellular uptake of 4-aminoquinoline antimalarial. Agents Actions Suppl. 1988;24:142–57.PubMed

34.

Browning D.J. Pharmacology of Chloroquine and Hydroxychloroquine. In: Hydroxychloroquine and Chloroquine Retinopathy. Springer, New York, NY. 2014. https://doi.org/10.1007/978-1-4939-0597-3_2.

35.

Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6:16.CrossRef

36.

Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269–71.CrossRef

37.

Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). Clin Infect Dis. 2020. https://doi.org/10.1093/cid/ciaa237.CrossRefPubMedPubMedCentral

38.

Garcia-Cremades M, Solans BP, Hughes E, et al. Optimizing hydroxychloroquine dosing for patients with COVID-19: an ifntegrative modeling approach for effective drug response. Clin Pharmacol Ther. 2020. https://doi.org/10.1002/cpt.1856.CrossRefPubMedPubMedCentral

39.

Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in the treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14:72–3.CrossRef

40.

Borba MGS, Val FFA, Sampaio VS, et al. Effect of high vs. low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. JAMA Netw Open. 2020;3:e208857.CrossRef

41.

Petri M, Elkhalifa M, Li J, Magder LS, Goldman DW. Hydroxychloroquine blood levels predict hydroxychloroquine retinopathy. Arthritis Rheumatol. 2020;72:448–53.CrossRef

42.

Perinel S, Launay M, Botelho-Nevers E, et al. Towards optimization of hydroxychloroquine dosing in intensive care unit COVID-19 patients. Clin Infect Dis. 2020. https://doi.org/10.1093/cid/ciaa394.CrossRefPubMedPubMedCentral

43.

Durcan L, Clarke WA, Magder LS, Petri M. Hydroxychloroquine blood levels in systemic lupus erythematosus: clarifying dosing controversies and improving adherence. J Rheumatol. 2015;42:2092–7.CrossRef

44.

Al-Kofahi M, Jacobson P, Boulware DR, et al. Finding the dose for hydroxychloroquine prophylaxis for COVID-19; the desperate search for effectiveness. Clin Pharmacol Ther. 2020. https://doi.org/10.1002/cpt.1874.CrossRefPubMedPubMedCentral

45.

Boulware DR, Pullen MF, Bangdiwala AS, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for COVID-19. N Engl J Med. 2020. https://doi.org/10.1056/NEJMoa2016638.CrossRefPubMedPubMedCentral

46.

Tetu P, Hamelin A, Lebrun-Vignes B, et al. Prevalence of hydroxychloroquine-induced side-effects in dermatology patients: a retrospective survey of 102 patients. Ann Dermatol Venerol. 2018;145:395–404.CrossRef

47.

Drent M, Proesmans VLJ, Elfferich MDP, et al. Ranking self-reported gastrointestinal side effects of pharmacotherapy in sarcoidosis. Lung. 2020;198:395–403.CrossRef

48.

Srinivasa A, Tosounidou S, Godon C. Increased incidence of gastrointestinal side effects in patients taking hydroxychloroquine: a brand-related issue? J Rheumatol. 2017;44:398.CrossRef

49.

O’Laughlin JP, Mehta PH, Wong BC. Life-threatening severe QTc prolongation in patient with systemic lupus erythematosus due to hydroxychloroquine. Case Rep Cardiol. 2016;2016:4626279.PubMedPubMedCentral

50.

Jorge A, Ung C, Young LH, Melles RB, Choi HK. Hydroxychloroquine retinopathy-implications for research advances for rheumatology care. Nat Rev Rheumatol. 2018;14:693–703.CrossRef

51.

Mercuro NJ, Yen CF, Shim DJ. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020. https://doi.org/10.1001/jamacardio.2020.1834.CrossRefPubMedPubMedCentral

Title: The Pharmacokinetic and Pharmacodynamic Properties of Hydroxychloroquine and Dose Selection for COVID-19: Putting the Cart Before the Horse
Authors: Taylor Morrisette
Thomas P. Lodise
Marc H. Scheetz
Srijib Goswami
Jason M. Pogue
Michael J. Rybak
Publication date: 01-09-2020
Publisher: Springer Healthcare
Keywords: Chloroquin
Post-Exposure Prophylaxis
Pharmacokinetics
Chloroquin
SARS-CoV-2
COVID-19
Hydroxychloroquine
Published in: Infectious Diseases and Therapy / Issue 3/2020
Print ISSN: 2193-8229
Electronic ISSN: 2193-6382
DOI: https://doi.org/10.1007/s40121-020-00325-2

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

The Pharmacokinetic and Pharmacodynamic Properties of Hydroxychloroquine and Dose Selection for COVID-19: Putting the Cart Before the Horse

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2020

Correction to: A Systematic Review of the Clinical Utility of Cycle Threshold Values in the Context of COVID-19

Pulmonary Aspergillosis: An Evolving Challenge for Diagnosis and Treatment

Viral Respiratory Infections in Hematological Patients

Sex, Age, and Race Effects on Immunogenicity of MenB-FHbp, A Bivalent Meningococcal B Vaccine: Pooled Evaluation of Clinical Trial Data

Correction to: Vaccine Hesitancy as a Challenge or Vaccine Confidence as an Opportunity for Childhood Immunisation in India

Pharmacists’ Knowledge About the Impact of Augmented Renal Clearance on Antimicrobial Dosing in Critically Ill Patients: A Cross-Sectional Study

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page